Day One Biopharmaceuticals, Inc. (NasdaqGM: DAWN)
Health Care · Biotechnology · US
$—
— today · — 1Y
Day One Biopharmaceuticals, Inc. (NasdaqGM: DAWN) operates in the Biotechnology industry within the Health Care sector.
trading between 6.67 and 21.53.
Tweenvest scores Day One Biopharmaceuticals, Inc. across four factors: quality 36/100, value 67/100. Its strongest factor is value.
DAWN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $158.18M
- P/E
- —
- EPS
- -1.04
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $21.53
- 52-week low
- $6.67
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 181
- Next earnings
- —
About Day One Biopharmaceuticals, Inc.
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
- ISIN
- US23954D1090
- Founded
- 2018
- Listed since
- May 27, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.13 | -1.75% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.39 | -0.19% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.54 | -0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.64 | -0.58% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.30 | -1.23% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.41 | -7.82% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.